Introduction
The post-pubertal development of the mouse mammary gland during pregnancy and lactation is primarily controlled through systemically released steroid and peptide hormones of the ovary, adrenal, pituitary and placenta. However, the dramatic tissue remodelling that occurs within the gland itself is probably accomplished through the action of locally induced factors. It is now becoming apparent that many of the growth factors identi®ed as proto-oncogenes in mouse mammary tumour models, and by the genomic analysis of human breast tumour DNAs, have highlighted signalling pathways of potential importance to the tissue remodelling process that occurs during pregnancy. To test these ideas, transgenic mouse strategies have been exploited to assess the potential role of these factors in normal mammary gland development. In this review we discuss two examples where a knowledge of the signalling pathways implicated in mammary tumorigenesis have given new insights into the normal development of the mammary gland.
One of the earliest animal models of breast cancer was developed in the 1930's by inter-breeding of mice which were found to have spontaneous mammary tumours. In this way several lines of inbred mice were generated that display a high incidence of mammary carcinoma. Unexpectedly, in many lines the high tumour incidence was found to be caused by a virus, the mouse mammary tumour virus (MMTV), and not, as anticipated, due to the selection of tumour susceptibility genes in the mouse germ line. It is now known that MMTV is a retrovirus that causes mammary cancer by acting as an insertional mutagen (reviewed in Nusse, 1991; Peters, 1991) . During its replication cycle, the viral DNA is inserted into the genome at random sites to establish a provirus. As the provirus contains potent transcriptional enhancers, its integration near a somatic gene may cause the gene to be inappropriately expressed. In rare instances, activation of a cellular gene can confer a growth advantage to a cell, producing an expanded population of progeny cells susceptible to further genetic change and hence tumorigenesis. The mammary epithelium is particularly prone to neoplastic transformation by MMTV since this tissue is the major site of its replication with many cells acquiring one or more viral insertions. Therefore in the total of ®ve pairs of mammary glands each containing millions of cells there is a high probability of at least one or more cells acquiring a combination of viral and non-viral genetic alterations with the potential for neoplastic growth.
Growth factors and their receptors as proto-oncogenes in mammary cancer
An advantage of studying MMTV induced tumours is the ability to locate the genetic lesions associated with their development, since the provirus acts as a genetic marker for the cloning of the perturbed cellular locus. Clustering of proviruses at the same genetic locus in several dierent mammary tumours provided the evidence that these insertions represented common functionally important mutations that contributed to tumour induction. Moreover, further studies revealed that in each case, the provirus was found to have caused the expression of a gene which is normally silent in the mammary gland. This approach led to the identi®cation of several proto-oncogenes for the mouse mammary gland, that included members of the Wnt, Fibroblast growth factor (Fgf) and Notch gene families, and provided circumstantial evidence for their role in tumorigenesis (see Nusse, 1991) .
The subsequent development of techniques to generate transgenic mice facilitated the testing of candidate oncogenes in vivo. It has now been con®rmed by several laboratories, that ectopic expression of genes identi®ed at viral integration sites in the mammary epithelium invariably cause hyperplasia, and often result in frank neoplasia (Tsukamoto et al., 1988; Muller et al., 1990; Stamp et al., 1992; Gallahan et al., 1996) . Moreover, many tumours were shown to contain more than one virally activated oncogene, providing evidence for oncogene co-operation in vivo (Peters et al., 1986) . Transgenic mouse experiments have since con®rmed the co-operation of these oncogenes in tumour progression (Shackleford et al., 1993; MacArthur et al., 1995) . Among the potent *Correspondence: C Dickson Oncogene (2000) 19, 1097 ± 1101 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc dominant acting oncogenes for the mammary epithelium there are several genes encoding growth factors or their receptors, and these have provided models of mouse mammary carcinogenesis.
Fgf-signalling is involved in mammary lobuloalveolar development
Int-2/Fgf-3 was discovered as a candidate oncogene, transcriptionally activated by MMTV in mouse mammary tumours (Dickson et al., 1984) . At the time nothing was known about its normal function, so it was designated int-2 (common integration site 2), although it soon emerged that it was a member of the ®broblast growth factor family. In situ hybridization studies have revealed its complex spatial-temporal pattern of expression during mouse development, but it is essentially silent in adult tissues (Wilkinson et al., 1988 (Wilkinson et al., , 1989 Mansour et al., 1993) . Thus, Fgf-3 expression was not detected in normal mouse mammary tissue from virgin or pregnant mice . Con®rmation of its oncogenic potential in the mammary gland came from transgenic mouse studies, where its unscheduled synthesis resulted in mammary hyperplasia (Dickson et al., 1984; Muller et al., 1990) .
In cell culture Fgfs can act as mitogens, promote cell migration or modulate cellular dierentiation depending on the context (reviewed in Basilico and Moscatelli, 1992; McKeehan et al., 1998) . Hence it was suggested that Fgfs might play a role in normal mammary gland development, particularly since inappropriate expression of Fgf-3 resulted in abnormal mammary growth and tumorigenesis. Fgfs signal by binding high anity cell surface receptors, causing their dimerization and consequent activation of the cytoplasmic tyrosine kinase (reviewed in Johnson and Williams, 1993; McKeehan et al., 1998) ; Figure 1a . In mammals there are four FGF receptor genes (Fgfr-1 to Fgfr-4), but through alternative splicing of Fgfr-1 through to Fgfr-3, seven proto-type receptors with dierent FGF binding speci®cities are generated (see Ornitz et al., 1996) . Fgf-receptors contain two or three immunoglobin-like loops in the extracellular domain, a transmembrane element and a cytoplasmic tyrosine kinase. Fgf binding occurs at the two membrane proximal Ig loops, and it is one of these loops which is encoded by an alternative exon designated IIIb or IIIc.
To determine the role Fgfs might have in postpubertal mammary gland development, we sought to compromise Fgf signalling in the mammary epithelium. Fgf signalling speci®city is complex as most Fgf-ligands activate several Fgf-receptor species (see Ornitz et al., 1996) . Furthermore, many tissues including the mammary gland express multiple members of the Fgf and Fgf-receptor families (Coleman-Krnacik and Rosen, 1994) . Consequently, the approach taken was to express a transgene encoding a dominant negative form of an Fgf-receptor expressed in normal mammary epithelium but which also had the potential to be activated by Fgf-3.
Fgf-3 has been shown to bind two receptor isoforms with high anity, Fgfr-1(IIIb) and Fgfr-2(IIIb), and both are present in mammary tissue (Mathieu et al., 1995) . Since Fgfr-2(IIIb) has a broader ligand speci®city than Fgfr-1(IIIb), this made it a preferred choice for a dominant negative receptor transgene since it could bind more potential ligands. The dominant negative Fgfr-2(IIIb) receptor gene was constructed by removing the cytoplasmic tyrosine kinase domain from an appropriate mouse cDNA, leaving the extracellular and transmembrane coding domains intact (Figure 1b) . Hence, ligand mediated dimerization of the truncated receptor protein potentiates the sequestration of wildtype endogenous receptor as inactive heterodimers (Figure 1b) .
The MMTV LTR shows a high level of promoter activity in the mammary epithelium, particularly during pregnancy and was therefore selected to drive the dominant negative-receptor construct. Also its relative tissue speci®city, makes it suitable to direct expression of a dominant negative receptor in this cell type, without compromising other tissues where the receptor is normally expressed. However, two criteria must be satis®ed for the dominant negative-receptor to eectively inhibit Fgf signalling: ®rstly, it needs to be expressed at a substantially higher level (410 fold) than the endogenous receptor so that formation of endogenous wild-type receptor pairs are rare events (Figure 1) . Secondly, the transgene must be expressed in most of the epithelial cells of the mammary gland so that non-expressing cells cannot compensate for the loss of function in the transgene expressing cells. In the adult virgin mammary gland, expression of the dominant negative Fgfr-2(IIIb) transgene was shown to have no discernible eect (Jackson et al., 1997) . However, from mid-pregnancy, the mammary glands of transgenic mice showed a distinct reduction in lobuloalveolar development that continued into lactation (Figure 2 ), although those lobules that developed appeared to be histologically normal, and the alveoli were ®lled with milk ( Figure 3) . The reduction in the number of lobuloalveolar structures gave rise to subnormal levels of milk production and this was re¯ected in the runted appearance of the ospring of transgenic mothers. Therefore, signalling by an Fgf that activates Fgfr-2(IIIb) is an important facet of normal mammary gland development during pregnancy. This ®nding is consistent with the detection in mouse mammary glands of Fgf-7 and Fgf-10, two ligands speci®c for this receptor (unpublished data S. Werner et al). However, in the normal gland these ligands would be expected to give rise to a paracrine stimulation of the mammary epithelium, an activity ultimately under endocrine control. This is in contrast to the autocrine mechanism of abnormal growth caused by inappropriate Fgf-3 expression.
Cyclin D1 is critical for mammary growth and dierentiation
The discovery of Fgf-3 as an oncogene for the mouse mammary gland prompted the analysis of this locus in Figure 2 Whole mount preparations of mammary gland from pregnant mice. Top panels: Tissues taken at 18 days of pregnancy from control and transgenic mice as indicated. Lower panels: Tissue taken from mice 1 day post partum. Mammary glands from both DN-Fgfr-2(IIIb) and Cyl-1 7/7 mice show a reduced lobuloalveolar density. In 1 day post partum samples the alveoli in the mammary gland of the DN-Fgfr-2(IIIb) mice are extended with milk as are the controls, but those of the Cyl-1 7/7 gland remain contracted Figure 3 Histological sections of mammary tissue from 1 day post partum mice. DN-Fgfr-2(IIIb) transgenic tissue (left panel) shows a reduction in the density of lobuloalveoli compared to control (center panel). However, lactogenesis appears relatively normal in the DN-Fgfr-2(IIIb) mice. By contrast, Cyl-1 7/7 mammary tissue (right panel) shows both a reduced lobuloalveolar density and a marked reduction of lactogenesis human breast tumour DNAs. The FGF-3 locus which was mapped to chromosome 11q13 was shown to be ampli®ed in approximately 15% of breast tumour DNA samples (Fantl et al., 1990) . However, expression of FGF-3 RNA was extremely rare in these tumours indicating that it was unlikely to be involved in their induction. This suggested that another gene on the amplicon fortuitously linked to FGF-3 was driving tumour development. Further analysis of the ampli®ed DNA from these tumours revealed that the cyclin D1 gene (CCND1) was likely to be the candidate oncogene since it was closely linked to and always co-ampli®ed with FGF-3 (Lammie et al., 1991) . Moreover, immunohistochemistry revealed that cyclin D1 is expressed at elevated levels in 40% of tumour samples, considerably more than the subset accounted for by gene ampli®cation (Bartkova et al., 1994; Gillett et al., 1994) . Additional evidence of cyclin D1 as a potential oncogene was provided by studies that showed that the CCND1 locus was involved in chromosomal translocations in a subset of lymphomas and parathyroid adenomas (for review see . In the mouse, inappropriate expression of a cyclin D1 transgene in the mammary epithelium caused a late but signi®cant incidence of mammary hyperplasia, strengthening its potential involvement in mammary cancer (Wang et al., 1994) .
In parallel with these studies, the normal function of cyclin D1 was under investigation. It is now known that cyclin D1 is one of three closely related proteins, all widely expressed, that are regulatory subunits for cyclin dependent kinases (CDK) CDK4 and CDK6 (reviewed in Sherr, 1995) . The CDK/cyclin D complexes are activated during the G1 phase of the cell division cycle and phosphorylate the retinoblastoma (Rb) family of proteins (reviewed in Weinberg, 1995; Sherr, 1996) . They are believed, along with cyclin E, to release the block on entry into DNA synthesis and cell division imposed by the Rb tumour suppressor gene. Thus an increase in cyclin D1 expression could perturb the negative regulation on cell division imposed by Rb, which in turn could result in abnormal cell proliferation.
To investigate more precisely the role of cyclin D1 in vivo, mutant mice lacking the protein were generated (Fantl et al., 1995; Sicinski et al., 1995) . Despite the predicted crucial role of cyclin D1 in cell division, Cyl-1 7/7 mice are viable and fertile. Nevertheless, they suer from two well characterised phenotypic abnormalities; retinopathy and, during pregnancy, defective mammary gland development that results in an inability to rear their young. While the virgin mammary glands of cyclin D1 de®cient mice are not noticeably dierent from comparable controls, there is a distinct retardation of lobuloalveolar development which is apparent by 7.5 days. This continues to term resulting in a poor lactogenic response (Figures 2 and   3 ). Thus the appearance of milk proteins was shown to be signi®cantly delayed and reduced in amount compared with control glands (Fantl et al., 1999) . Transplantation of mammary epithelium from mutant mice into the empty fat pad of histocompatible wildtype mice showed the same mammary gland phenotype as the Cyl-1 7/7 mice demonstrating that the defect in the mammary gland is a cell autonomous property of its epithelial component (Fantl et al., 1999) .
Discussion
Morphologically there is a similarity of phenotype observed between the dominant negative Fgfr-2(IIIb) transgenic mice and those lacking cyclin D1. Mice expressing a dominant negative Fgfr-2(IIIb) receptor show a signi®cantly reduced density of lobuloalveolar structures, although the majority of alveoli that develop appear to dierentiate fully and produce milk. This might be explained by functional compensation through a parallel signalling pathway, or by the dominant negative receptor failing to fully suppress endogenous receptor signalling due to inadequate levels of transgene expression in some cells. Nevertheless, the results clearly demonstrate a need for FGF signalling to obtain proper development of the mammary gland during pregnancy. Similarly, the Cyl-1 7/7 mice also showed a reduction of lobuloalveolar development, but the alveoli also gave a poor lactogenic response. As evidenced by an inability to suckle their young, the Cyl-1 7/7 mice appear to have a more severe abnormality. Nevertheless, even in the absence of cyclin D1, signi®cant growth and dierentiation of the mammary gland occurs during pregnancy indicating a degree of functional redundancy for this gene product. The main role of cyclin D1 in the mammary gland seems to be to ensure that the rate of proliferation and dierentiation of the gland is such that at parturition the gland is suciently well developed to provide adequate milk to nurture the ospring (Fantl et al., 1999) . Thus, while both types of transgenic mice demonstrated a compromised proliferative capacity of the mammary epithelium, in the Cyl-1 7/7 mice dierentiation of the mammary epithelial cells was also retarded. It is interesting that the adult mammary epithelium is one of the few mouse cell lineages that is strongly dependent on cyclin D1 for its normal function.
The two genes selected for the generation of the transgenic lines of mice described was prompted by their involvement in signal transduction pathways in mammary tumorigenesis. We have now demonstrated that these same pathways are intimately associated with the normal development of the mammary gland during pregnancy, reinforcing the strong links between tumour and developmental biology.
